A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 172 in Subjects With Relapsed / Refractory Renal Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2016
At a glance
- Drugs AMG 172 (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Amgen
- 07 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Oct 2014 Planned number of patients changed from 60 to 82 as reported by ClinicalTrials.gov.